2:05 PM
Jul 18, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Colorectal cancer

Patient sample, in vitro, cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were associated with poor overall survival. In silico screening of a...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >